New York, May 30, 2026, 09:23 (EDT)
Clorox shares ended the holiday-shortened week sharply lower after Chair and Chief Executive Linda Rendle said she would step down for health reasons, putting succession risk on top of weak sales growth and a reduced profit outlook.
The stock closed Friday at $90.02, down 6.42% on the day and about 5.4% from the prior Friday’s close of $95.11. Trading volume rose to 4.6 million shares, above recent sessions, as investors marked down the Oakland, California-based maker of bleach, Pine-Sol, Glad bags and other household brands.
The timing matters. U.S. exchanges were closed Monday for Memorial Day, and the New York Stock Exchange does not trade on Saturday; its regular core session runs from 9:30 a.m. to 4 p.m. ET on trading days. That leaves investors with a weekend to digest the board search and a short runway before Clorox faces analysts again next week.
Clorox said Thursday that Rendle, who has spent 23 years at the company, asked the board to begin a CEO search. She will remain chair and CEO until a successor is named and then serve as an adviser for a period after the appointment, with the search led by an independent board committee and an executive search firm.
In a personal note, Rendle said she is cancer-free after an early-stage breast cancer diagnosis, but that side effects from ongoing treatment to prevent recurrence had prompted her to rethink her health and family priorities. “Nothing changes in the short term,” she wrote, adding that she remains focused on strategy, execution and the transition. The Clorox Company
The selloff came because the leadership news landed on a stock already under pressure. In late April, Clorox reported flat fiscal third-quarter net sales of $1.67 billion, while gross margin fell to 43.2% from 44.6% a year earlier. The company forecast fiscal 2026 net sales would fall 6% and adjusted earnings per share — profit per share excluding specified items — would be $5.45 to $5.65, below its earlier range.
The move also stood out against the wider tape. The S&P 500 rose 0.2% Friday and finished higher for a ninth straight week, while the Dow added 0.7% and the Nasdaq gained 0.2%, helped by technology shares.
Among household and consumer staples names, Clorox fell harder than peers. Procter & Gamble dropped 1.6%, Kimberly-Clark lost 2.6% and Colgate-Palmolive slipped 1.7%, while the Consumer Staples Select Sector SPDR Fund, a broad basket of everyday-goods stocks, fell 1.8%.
Analyst sentiment was already cautious after the April outlook cut. Goldman Sachs analyst Bonnie Herzog lowered the firm’s target price on Clorox to $83 from $94 and kept a Sell rating, saying the quarter’s modest earnings beat was outweighed by weaker guidance, cost pressure, the Purell-maker GOJO integration and the company’s ERP software transition — ERP meaning the back-office systems used to manage orders, inventory and finance.
Not all views are as bleak. Morningstar analyst Erin Lash’s May 28 note on the CEO news framed the shares as “a bargain,” a sign some investors may look at the drop as valuation relief rather than a broken story. Morningstar
The week ahead brings an obvious checkpoint. Clorox said Rendle and Chief Financial Officer Luc Bellet are scheduled to speak at the dbAccess Global Consumer Conference in Paris on Wednesday, June 3, with a webcast at 6 a.m. ET. Investors will listen for any added detail on the search, the GOJO deal, gross margin pressure and whether the lowered fiscal 2026 targets are holding.
But the risk is that the CEO search takes longer than investors like, or that the next leader inherits a tougher reset than the market is pricing. A cleaner handoff, better retail demand and cost savings could steady the stock; another guide-down, weaker market share or slower GOJO integration would leave Clorox exposed near the low end of its 52-week range.
